Intercept Pharmaceuticals’ (ICPT) Underweight Rating Reaffirmed at Cantor Fitzgerald

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)‘s stock had its “underweight” rating reaffirmed by Cantor Fitzgerald in a research note issued on Wednesday. They currently have a $69.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target indicates a potential downside of 29.68% from the company’s current price.

Other research analysts have also issued research reports about the stock. Cowen and Company reiterated a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Monday, June 12th. Credit Suisse Group set a $201.00 price objective on shares of Intercept Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, June 3rd. BidaskClub upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Wedbush reiterated a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Monday, July 31st. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $275.00 price objective on shares of Intercept Pharmaceuticals in a research note on Sunday, July 30th. One analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $205.04.

Shares of Intercept Pharmaceuticals (NASDAQ ICPT) opened at 98.12 on Wednesday. The stock’s 50 day moving average is $112.60 and its 200-day moving average is $117.12. Intercept Pharmaceuticals has a 12-month low of $90.53 and a 12-month high of $172.95. The stock’s market cap is $2.46 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($3.46) EPS for the quarter, topping the consensus estimate of ($3.62) by $0.16. The firm had revenue of $30.89 million during the quarter, compared to analyst estimates of $27.50 million. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. Intercept Pharmaceuticals’s revenue was up 459.6% on a year-over-year basis. During the same quarter in the previous year, the business posted ($3.14) EPS. Equities analysts expect that Intercept Pharmaceuticals will post ($14.05) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This story was originally reported by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/2887784/intercept-pharmaceuticals-icpt-underweight-rating-reaffirmed-at-cantor-fitzgerald.html.

In other news, insider Lisa Bright sold 394 shares of the company’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $121.33, for a total value of $47,804.02. Following the sale, the insider now directly owns 23,619 shares of the company’s stock, valued at approximately $2,865,693.27. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Mark Pruzanski sold 40,000 shares of the company’s stock in a transaction on Monday, June 26th. The shares were sold at an average price of $130.80, for a total transaction of $5,232,000.00. Following the completion of the sale, the chief executive officer now directly owns 611,718 shares in the company, valued at $80,012,714.40. The disclosure for this sale can be found here. Insiders sold a total of 48,013 shares of company stock worth $6,198,747 over the last ninety days. Insiders own 4.50% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. boosted its holdings in shares of Intercept Pharmaceuticals by 0.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,020 shares of the biopharmaceutical company’s stock valued at $229,000 after acquiring an additional 14 shares during the last quarter. Public Employees Retirement Association of Colorado boosted its holdings in shares of Intercept Pharmaceuticals by 1.1% in the 2nd quarter. Public Employees Retirement Association of Colorado now owns 4,111 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 43 shares during the last quarter. Janney Montgomery Scott LLC boosted its holdings in shares of Intercept Pharmaceuticals by 1.8% in the 2nd quarter. Janney Montgomery Scott LLC now owns 3,435 shares of the biopharmaceutical company’s stock valued at $416,000 after acquiring an additional 62 shares during the last quarter. WFG Advisors LP boosted its holdings in shares of Intercept Pharmaceuticals by 16.4% in the 2nd quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 125 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Intercept Pharmaceuticals by 14.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock valued at $118,000 after acquiring an additional 132 shares during the last quarter. 82.19% of the stock is currently owned by institutional investors and hedge funds.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2017 Ticker Report. Google+.